Addition of exogenous polypeptides on the mammalian reovirus outer capsid using reverse genetics

Journal of Virological Methods

Volumn 179, Issue 2, 2012, Pages 342-350

  Brochu Lafontaine, Virginie ^a   Lemay, Guy ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Epitope; Reovirus; Reverse genetics; Tag

Indexed keywords

AMINO ACID DERIVATIVE; CAPSID PROTEIN; NUCLEIC ACID; NUCLEOTIDE; POLYPEPTIDE; SIGMA1 OUTER CAPSID PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MAMMALIAN ORTHOREOVIRUS; MOLECULAR SIZE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE GENETICS; SEQUENCE TAGGED SITE; STOP CODON; VIRUS CAPSID;

ANIMALS; CAPSID PROTEINS; CELL LINE; CERCOPITHECUS AETHIOPS; GENE EXPRESSION; GENETIC ENGINEERING; GENETIC VECTORS; MICE; ORTHOREOVIRUS, MAMMALIAN; PLASMIDS; RECOMBINANT FUSION PROTEINS; REVERSE GENETICS;

MAMMALIA; MIRIDAE; ORTHOREOVIRUS;

EID: 84855516240     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2011.11.021     Document Type: Article

References (51)

1. Alain T., Kim T.S., Lun X., Liacini A., Schiff L.A., Senger D.L., Forsyth P.A. Proteolytic disassembly is a critical determinant for reovirus oncolysis. Mol. Ther. 2007, 15:1512-1521.
2. Antar A.A., Konopka J.L., Campbell J.A., Henry R.A., Perdigoto A.L., Carter B.D., Pozzi A., Abel T.W., Dermody T.S. Junctional adhesion molecule-A is required for hematogenous dissemination of reovirus. Cell Host Microbe 2009, 5:59-71.
3. Bell J.C., Kirn D. MicroRNAs fine-tune oncolytic viruses. Nat. Biotechnol. 2008, 26:1346-1348.
4. Blechacz B., Russell S.J. Measles virus as an oncolytic vector platform. Curr. Gene Ther. 2008, 8:162-175.
5. Boehme K.W., Guglielmi K.M., Dermody T.S. Reovirus nonstructural protein sigma1s is required for establishment of viremia and systemic dissemination. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:19986-19991.
6. Buchholz U.J., Finke S., Conzelmann K.K. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J. Virol. 1999, 73:251-259.
7. Campadelli-Fiume G., De Giovanni C., Gatta V., Nanni P., Lollini P.-L., Menotti L. Rethinking herpes simplex virus: the way to oncolytic agents. Rev. Med. Virol. 2011, (May). [Epub ahead of print]. 10.1002/rmv.691.
8. Chappell J.D., Prota A.E., Dermody T.S., Stehle T. Crystal structure of reovirus attachment protein sigma1 reveals evolutionary relationship to adenovirus fiber. EMBO J. 2002, 21:1-11.
9. Coyne C.B. The distinct roles of JAM-A in reovirus pathogenesis. Cell Host Microbe 2009, 5:3-5.
10. Danthi P., Coffey C.M., Parker J.S., Abel T.W., Dermody T.S. Independent regulation of reovirus membrane penetration and apoptosis by the mu1 phi domain. PLoS Pathog. 2008, 4. e1000248.
11. Danthi P., Kobayashi T., Holm G.H., Hansberger M.W., Abel T.W., Dermody T.S. Reovirus apoptosis and virulence are regulated by host cell membrane penetration efficiency. J. Virol. 2008, 82:161-172.
12. Danthi P., Guglielmi K.M., Kirchner E., Mainou B., Stehle T., Dermody T.S. From touchdown to transcription: the reovirus cell entry pathway. Curr. Top. Microbiol. Immunol. 2010, 343:91-119.
13. Desmyter J., Melnick J.L., Rawls W.E. Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero). J. Virol. 1968, 2:955-961.
14. Emeny J.M., Morgan M.J. Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production. J. Gen. Virol. 1979, 43:247-252.
15. Forrest J.C., Dermody T.S. Reovirus receptors and pathogenesis. J. Virol. 2003, 77:9109-9115.
16. Golden J.W., Linke J., Schmechel S., Thoemke K., Schiff L.A. Addition of exogenous protease facilitates reovirus infection in many restrictive cells. J. Virol. 2002, 76:7430-7443.
17. Harrington K.J., Vile R.G., Melcher A., Chester J., Pandha H.S. Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev. 2010, 21:91-98.
18. Kelly E.J., Hadac E.M., Greiner S., Russell S.J. Engineering microRNA responsiveness to decrease virus pathogenicity. Nat. Med. 2008, 14:1278-1283.
19. Kelly K., Nawrocki S., Mita A., Coffey M., Giles F.J., Mita M. Reovirus-based therapy for cancer. Expert Opin. Biol. Ther. 2009, 9:817-830.
20. Kim M., Garant K.A., zur Nieden N.I., Alain T., Loken S.D., Urbanski S.J., Forsyth P.A., Rancourt D.E., Lee P.W.K., Johnston R.N. Attenuated reovirus displays oncolysis with reduced host toxicity. Br. J. Cancer 2011, 104:290-299.
21. Kirchner E., Guglielmi K.M., Strauss H.M., Dermody T.S., Stehle T. Structure of reovirus sigma1 in complex with its receptor junctional adhesion molecule-A. PLoS Pathog. 2008, 4:e1000235.
22. Kobayashi T., Antar A.A., Boehme K.W., Danthi P., Eby E.A., Guglielmi K.M., Holm G.H., Johnson E.M., Maginnis M.S., Naik S., Skelton W.B., Wetzel J.D., Wilson G.J., Chappell J.D., Dermody T.S. A plasmid-based reverse genetics system for animal double-stranded RNA viruses. Cell Host Microbe 2007, 1:147-157.
23. Kobayashi T., Ooms L.S., Chappell J.D., Dermody T.S. Identification of functional domains in reovirus replication proteins muNS and mu2. J. Virol. 2009, 83:2892-2906.
24. Kobayashi T., Ooms L.S., Ikizler M., Chappell J.D., Dermody T.S. An improved reverse genetics system for mammalian orthoreoviruses. Virology 2010, 398:194-200.
25. Kolodziej P.A., Young R.A. Epitope tagging and protein surveillance. Methods Enzymol. 1991, 194:508-519.
26. Lal R., Harris D., Postel-Vinay S., de Bono J. Reovirus: rationale and clinical trial update. Curr. Opin. Mol. Ther. 2009, 11:532-539.
27. Lemay G. La génétique inverse dans l'étude des réovirus: Progrès, obstacles et développements futurs. Virologie 2011, 15:53-62.
28. Loken S.D., Norman K., Hirasawa K., Nodwell M., Lester W.M., Demetrick D.J. Morbidity in immunosuppressed (SCID/NOD) mice treated with reovirus (Dearing 3) as an anti-cancer biotherapeutic. Cancer Biol. Ther. 2004, 3:734-738.
29. Marcato P., Shmulevitz M., Pan D., Stoltz D., Lee P.W. Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol. Ther. 2007, 15:1522-1530.
30. Mathis J.M., Stoff-Khalili M.A., Curiel D.T. Oncolytic adenoviruses - selective retargeting to tumor cells. Oncogene 2005, 24:7775-7791.
31. Mercier G.T., Campbell J.A., Chappell J.D., Stehle T., Dermody T.S., Barry M.A. A chimeric adenovirus vector encoding reovirus attachment protein sigma1 targets cells expressing junctional adhesion molecule 1. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:6188-6193.
32. Middleton J.K., Agosto M.A., Severson T.F., Yin J., Nibert M.L. Thermostabilizing mutations in reovirus outer-capsid protein μ1 selected by heat inactivation of infectious subvirion particles. Virology 2007, 361:412-425.
33. Parashar K., Tarlow M.J., McCrae M.A. Experimental reovirus type 3-induced murine biliary tract disease. J. Pediatr. Surg. 1992, 27:843-847.
34. Rouault é., Lemay G. Incorporation of epitope-tagged viral σ3 proteins to reovirus virions. Can. J. Microbiol. 2003, 49:407-417.
35. Rudd P., Lemay G. Correlation between interferon sensitivity of reovirus isolates and ability to discriminate between normal and Ras-transformed cells. J. Gen. Virol. 2005, 86:1489-1497.
36. Schagen F.H., Wensveen F.M., Carette J.E., Dermody T.S., Gerritsen W.R., van Beusechem V.W. Genetic targeting of adenovirus vectors using a reovirus sigma1-based attachment protein. Mol. Ther. 2006, 13:997-1005.
37. Schelling P., Campbell J.A., Stehle T., Dermody T.S. Structural basis of mammalian orthoreovirus cell attachment. Segmented Double-Stranded RNA Viruses: Structure and Molecular Biology 2008, 147-171. Caister Academic Press. J.T. Patton (Ed.).
38. Schneider B.L., Seufert W., Steiner B., Yang Q.H., Futcher A.B. Use of polymerase chain reaction epitope tagging for protein tagging in Saccharomyces cerevisiae. Yeast 1995, 11:1265-1274.
39. Shmulevitz M., Pan L.Z., Garant K., Pan D., Lee P.W. Oncogenic Ras promotes reovirus spread by suppressing IFN-beta production through negative regulation of RIG-I signaling. Cancer Res. 2010, 70:4912-4921.
40. Smakman N., van den Wollenberg D.J., Borel Rinkes I.H., Hoeben R.C., Kranenburg O. Sensitization to apoptosis underlies KrasD12-dependent oncolysis of murine C26 colorectal carcinoma cells by reovirus T3D. J. Virol. 2005, 79:14981-14985.
41. Strong J.E., Coffey M.C., Tang D., Sabinin P., Lee P.W. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J. 1998, 17:3351-3362.
42. Thirukkumaran C., Morris D.G. Oncolytic viral therapy using reovirus. Methods Mol. Biol. 2009, 542:607-634.
43. Tsuruta Y., Pereboeva L., Glasgow J.N., Luongo C.L., Komarova S., Kawakami Y., Curiel D.T. Reovirus fiber incorporated into adenovirus serotype 5 enhances infectivity via a CAR-independent pathway. Biochem. Biophys. Res. Commun. 2005, 335:205-214.
44. Tsuruta Y., Pereboeva L., Glasgow J.N., Rein D.T., Kawakami Y., Alvarez R.D., Rocconi R.P., Siegal G.P., Dent P., Fisher P.B., Curiel D.T. A mosaic fiber adenovirus serotype 5 vector containing reovirus sigma 1 and adenovirus serotype 3 knob fibers increases transduction in an ovarian cancer ex vivo system via a coxsackie and adenovirus receptor-independent pathway. Clin. Cancer Res. 2007, 13:2777-2783.
45. Tyler K.L., Sokol R.J., Oberhaus S.M., Le M., Karrer F.M., Narkewicz M.R., Tyson R.W., Murphy J.R., Low R., Brown W.R. Detection of reovirus RNA in hepatobiliary tissues from patients with extrahepatic biliary atresia and choledochal cysts. Hepatology 1998, 27:1475-1482.
46. van den Wollenberg D.J., van den Hengel S.K., Dautzenberg I.J., Cramer S.J., Kranenburg O., Hoeben R.C. A strategy for genetic modification of the spike-encoding segment of human reovirus T3D for reovirus targeting. Gene Ther. 2008, 15:1567-1578.
47. Van Den Wollenberg D.J., Van Den Hengel S.K., Dautzenberg I.J., Kranenburg O., Hoeben R.C. Modification of mammalian reoviruses for use as oncolytic agents. Expert Opin. Biol. Ther. 2009, 9:1509-1520.
48. van Houdt W.J., Smakman N., van den Wollenberg D.J., Emmink B.L., Veenendaal L.M., van Diest P.J., Hoeben R.C., Borel Rinkes I.H., Kranenburg O. Transient infection of freshly isolated human colorectal tumor cells by reovirus T3D intermediate subviral particles. Cancer Gene Ther. 2008, 15:284-292.
49. Virgin H.W., Mann M.A., Fields B.N., Tyler K.L. Monoclonal antibodies to reovirus reveal structure/function relationships between capsid proteins and genetics of susceptibility to antibody action. J. Virol. 1991, 65:6772-6781.
50. Wilson I.A., Niman H.L., Houghten R.A., Cherenson A.R., Connolly M.L., Lerner R.A. The structure of an antigenic determinant in a protein. Cell 1984, 37:767-778.
51. Zurney J., Kobayashi T., Holm G.H., Dermody T.S., Sherry B. Reovirus mu2 protein inhibits interferon signaling through a novel mechanism involving nuclear accumulation of interferon regulatory factor 9. J. Virol. 2009, 83:2178-2187.